ACT China II 2012

December 2012, Guangzhou, China International speakers: Drs. Patrick G. Johnston, Lillian L. Siu, Richard L. Schilsky, J. Jack Lee CSCO speakers: Drs. Yilong Wu, Shukui Qin, Jin Li, Shun Lu, Tony S. K. Mok, Binghe Xu, Ning Liao

[View program]

Charter Sponsor: Sanofi Additional Sponsors: Boehringer Ingelheim, Quintiles, Roche In-Kind Support: ASCO, Conquer Cancer Foundation, AlphaMed Press

Video Lectures from ACT China II 2012

The videos below are in English. You can watch these videos in Chinese.
请点击此处播放中文版演讲视频。

November 30th

Ethics in Clinical Research
Patrick Johnston, MD, PhD
Phase I Clinical Trials: Objectives, Design, and Endpoints
Lillian L. Siu, MD
Incorporating Biomarkers in Phase I Clinical Trials - Contribution to Phase II and III
Prof Jin Li

December 1st

You're in Charge: Principal Investigator Responsibilities
Richard L. Schilsky, MD
Phase II Clinical Trials
Richard L. Schilsky, MD
Statistical Considerations for Phase II Clinical Trials and Adaptive Designs
J. Jack Lee, PhD, DDS
The Importance of Cooperative Network for Clinical Trials in China
Professor Wu Yi-long
Phase I Dose-escalation Study of Trametinib and Cisplatin in Patients with Advanced Soild Tumors
Xuening Yang
A Multi-center, Randomized Phase II Trial of Trametinib Vs. Pemetrexed in Second Line Treatment of Advanced Lung Adenocarcinoma with Wild-type AGFR/ALK
Honghong Yan
Phase II Study Design for Tivantinib in Breast Cancer
David Liu, MD, PhD
Phase II Clinical Trial Development for Tivatinib (ARQ 197) in GI Cancers
Xu Li
Phase III Trial Design
Tony Mok, MD
Statistical Considerations for Phase III Randomized Trials, Interim Analysis, and Data Monitoring
Jack Lee, PhD, DDS

December 2nd

Challenges in Colorectal Cancer
Patrick Johnston, MD, PhD
Building Bridges to Conquer Cancer
Doug Pyle, ASCO
ACT China II Roundtable
CSCO and Visiting faculty

 

The videos below are in Chinese. You can watch these videos in English.
请点击此处播放英文版演讲视频。

November 30th

Ethics in Clinical Research (中文)
Patrick Johnston, MD, PhD
Phase I Clinical Trials: Objectives, Design, and Endpoints (中文)
Lillian L. Siu, MD
Incorporating Biomarkers in Phase I Clinical Trials - Contribution to Phase II and III (中文)
Prof Jin Li

Pharmacokinetics, Pharmacodynamics, and Identifying Adverse Events in Phase I Clinical Trials (中文)
Lillian L. Siu, MD

December 1st

You're in Charge: Principal Investigator Responsibilities (中文)
Richard L. Schilsky, MD
Phase II Clinical Trials (中文)
Richard L. Schilsky, MD
Statistical Considerations for Phase II Trials and Adaptive Designs (中文)
J. Jack Lee, PhD, DDS
The Importance of Cooperative Network for Clinical Trials in China (中文)
Professor Wu Yi-long
Phase I Dose-escalation Study of Trametinib and Cisplatin in Patients with Advanced Soild Tumors (中文)
Xuening Yang
A Multi-center, Randomized Phase II Trial of Trametinib Vs. Pemetrexed in Second Line Treatment of Advanced Lung Adenocarcinoma with Wild-type AGFR/ALK (中文)
Honghong Yan
Phase II Study Design for Tivantinib in Breast Cancer (中文)
David Liu, MD, PhD
Phase II Clinical Trial Development for Tivatinib (ARQ 197) in GI Cancers (中文)
Xu Li
Phase III Trial Design (中文)
Tony Mok, MD
Statistical Considerations for Phase III Randomized Trials, Interim Analysis, and Data Monitoring (中文)
Jack Lee, PhD, DDS

December 2nd

Challenges in Colorectal Cancer (中文)
Patrick Johnston, MD, PhD
Building Bridges to Conquer Cancer (中文)
Doug Pyle, ASCO
ACT China II Roundtable (中文)
CSCO and Visiting faculty